Diffuse Large B Cell Lymphoma Clinical Trials

49 studies are recruiting for diffuse large b cell lymphoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL

   The purpose of this clinical trial is to assess the safety and tolerability of ration therapy followed by receiving epcoritamab or glofitamab in patients with relapsed/refractory diffuse large B-cell lymphoma.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah

   Run by

   University of Utah

   See if you can join NCT07528352 on ClinicalTrials.gov

2. IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL

   This study is being done to determine the safety, efficacy and tolerability of a single 50 mCi dose of 131I-Apamistamab given prior to FDA approved (commercially available) infusion in patients with Relapsed or refractory (R/R) non-Hodgkin lymphoma.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Texas Southwestern Medical Center, Dallas, Texas

   Run by

   University of Texas Southwestern Medical Center

   See if you can join NCT06768905 on ClinicalTrials.gov

3. Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

   Patients will receive one of two conditioning regimens (BEAM or CBV) before receiving an autologous stem cell transplant (ASCT). If patients achieve either complete, partial, or stable response following ASCT, they will receive an IV dose of Polatuzumab Vedotin once every 21 days until they receive…

   Stage

   Phase 1

   Ages

   12 to 70

   Site

   New York Medical Center, Valhalla, New York

   Run by

   New York Medical College

   See if you can join NCT04491370 on ClinicalTrials.gov

4. SynKIR-310 for Relapsed/Refractory B-NHL

   This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Colorado Blood Cancer Institute, part of Sarah Cannon Cancer Institute, Denver, Colorado

   Locations

   5 in total

   Run by

   Verismo Therapeutics

   See if you can join NCT06544265 on ClinicalTrials.gov

5. This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

   This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standard therapy available or are intolerant of the same.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dana Farber Cancer Institute, Boston, Massachusetts

   Locations

   3 in total

   Run by

   Zumutor Biologics Inc.

   See if you can join NCT06451497 on ClinicalTrials.gov

6. CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

   This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells. This research study involves the study drugs: * CD79b-19 CAR T cells * Fludarabine and Cyclopho…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Run by

   Marcela V. Maus, M.D.,Ph.D.

   See if you can join NCT06026319 on ClinicalTrials.gov

7. Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

   This phase Ib/II trial studies the side effects and efficacy of maintenance acalabrutinib following cellular therapy in treating patients with large B-cell lymphoma at very high risk of the cancer coming back. Acalabrutinib is a small molecular inhibitor that may interfere with the ability of cance…

   Stage

   Phase 1

   Ages

   18 to 70

   Site

   UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

   Locations

   3 in total

   Run by

   Jonsson Comprehensive Cancer Center

   See if you can join NCT05256641 on ClinicalTrials.gov

8. CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

   This is a Phase I/II, interventional, single-arm, open-label, treatment study designed to evaluate the safety and efficacy of Interleukin-7 and Interleukin-15 (IL-7/IL-15) manufactured chimeric antigen receptor (CAR)-20/19-T cells as well as the feasibility of a flexible manufacturing schema in adu…

   Stage

   Phase 1

   Ages

   18 to 80

   Site

   Medical College of Wisconsin and Froedtert Hospital, Milwaukee, Wisconsin

   Run by

   Medical College of Wisconsin

   See if you can join NCT04186520 on ClinicalTrials.gov

9. Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

   This phase I trial studies the safety and side effects of cytomegalovirus (CMV) specific CD19-chimeric antigen receptor (CAR) T-cells along with the CMV-modified vaccinia Ankara (MVA) triplex vaccine following a stem cell transplant in treating patients with high grade B-cell non-Hodgkin lymphoma. …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope Medical Center, Duarte, California

   Run by

   City of Hope Medical Center

   See if you can join NCT05432635 on ClinicalTrials.gov

10. Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

    This is a pilot study; patients will receive 131-I apamistamab prior to CAR T-cell infusion in order to determine the maximum tolerated dose of 131-I apamistamab is exceeded at 75 mCi, and if so, to assess the safety of a step-down dose of 50 mCi.

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT04512716 on ClinicalTrials.gov

11. Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

    This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed or refractory B-cell malignancies. LP-168 is a small molecule inhibitor.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Duke Univerisity, Durham, North Carolina

    Locations

    4 in total

    Run by

    Newave Pharmaceutical Inc

    See if you can join NCT04775745 on ClinicalTrials.gov

12. Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

    This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel) for…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Banner University Medical Center - Tucson, Tucson, Arizona

    Locations

    87 in total

    Run by

    SWOG Cancer Research Network

    See if you can join NCT05633615 on ClinicalTrials.gov

13. ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL

    The purpose of this study is to 1) determine whether it is feasible to measure circulating tumor DNA (ctDNA) in real-time during standard treatment for newly diagnosed diffuse large B-cell lymphoma (DLBCL), and 2) evaluate the outcomes of participants with undetectable ctDNA in the middle of treatm…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Columbia University, New York, New York

    Run by

    Hua-Jay J Cherng, MD

    See if you can join NCT06693830 on ClinicalTrials.gov

14. Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+

    This study is a single-arm, open label, non-randomized, phase 2 trial of zanubrutinib in patients with diffuse large B-cell lymphoma (DLBCL) who have an MYD88 L265P mutation, a CD79B mutation, a NOTCH1 truncation, or who are CD5+ by immunohistochemistry (IHC).

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Virginia Commonwealth University, Richmond, Virginia

    Run by

    Virginia Commonwealth University

    See if you can join NCT06846463 on ClinicalTrials.gov

15. A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

    A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibit…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    St Vincent's Hospital, Darlinghurst, New South Wales

    Locations

    16 in total

    Run by

    OncoNano Medicine, Inc.

    See if you can join NCT06022029 on ClinicalTrials.gov

16. A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma

    The purpose of this study is to find out how many people with B-cell lymphoma who are at high risk for central nervous system/CNS relapse test positive for cerebral spinal fluid/CSF ctDNA but test negative for CNS involvement using standard tests. The study will also look at how often CNS relapse h…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06736613 on ClinicalTrials.gov

17. Emapalumab Prevention of CAR-T Cell Associated Toxicities

    This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-Hodgkin's lymphoma (NHL). The research study involves the following study interventions: * Fludarabine and cyclophosphamide (Lymphodepleting…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Marcela V. Maus, M.D.,Ph.D.

    See if you can join NCT06550141 on ClinicalTrials.gov

18. Long-term Follow-up Study of Patients Receiving CAR-T Cells

    This protocol is designed as a long-term follow-up study of participants who will receive CAR-T cells as part of a clinical trial at the Medical College of Wisconsin/ Froedtert Hospital. The clinical trials include the following: Phase 1 Study of CAR-20/19-T Cells in Patients with Relapsed Refracto…

    Stage

    Not phased

    Ages

    18 to 80

    Site

    Froedtert Hospital & Medical College of Wisconsin, Milwaukee, Wisconsin

    Run by

    Medical College of Wisconsin

    See if you can join NCT03375619 on ClinicalTrials.gov

19. Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment

    This study evaluates immune responses after CAR-T therapy to find out if CAR-T therapy reduces the effectiveness of the vaccines (vaccine immunity) against diseases such as measles, mumps and rubella, among others in patients with multiple myeloma and non-Hodgkin lymphoma.

    Stage

    Not phased

    Ages

    18 and older

    Site

    OHSU Knight Cancer Institute, Portland, Oregon

    Run by

    OHSU Knight Cancer Institute

    See if you can join NCT06784167 on ClinicalTrials.gov

20. Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

    The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this treatment for children, adolescents and young adults (CAYA) with relap…

    Stage

    Phase 2

    Ages

    3 to 31

    Site

    New York Medical College, Valhalla, New York

    Run by

    New York Medical College

    See if you can join NCT02393157 on ClinicalTrials.gov

21. Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

    This trial aims to demonstrate the feasibility of this approach to reliably generate product and to safely administer the product to patients who have B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia.

    Stage

    Phase 2

    Ages

    18 to 79

    Site

    AHN Cancer Institute - West Penn Hospital, Pittsburgh, Pennsylvania

    Run by

    John Lister

    See if you can join NCT05281809 on ClinicalTrials.gov

22. A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in Oncology

    Cancer is amongst the leading causes of disease-related morbidity and mortality. A major challenge in cancer treatment is the development of biology-informed, personalised treatment strategies. Recent advances in artificial intelligence (AI) and next-generation sequencing (NGS) technologies have sh…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Pittsburgh, Pittsburgh, Pennsylvania

    Locations

    5 in total

    Run by

    OWKIN

    See if you can join NCT06625203 on ClinicalTrials.gov

23. Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy

    In this study, invesigators propose to analyze 150 DLBCL patients, 50 MCL patients, and 100 FL patients to determine the clinical utility of ctDNA- as well as circulating tumor cell (CTC)-based MRD assessment in CAR therapy patients. The project detailed in this protocol will utilize the clonoSEQ p…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Stanford Cancer Center, Palo Alto, California

    Run by

    Adaptive Biotechnologies

    See if you can join NCT05255354 on ClinicalTrials.gov

24. Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

    This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia. Participants must be relapsed/refractory (having failed prior therapy)

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Goshen Center for Cancer Care, Goshen, Indiana

    Locations

    45 in total

    Run by

    Kartos Therapeutics, Inc.

    See if you can join NCT04502394 on ClinicalTrials.gov